A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/24/2019
Start Date:January 12, 2017
End Date:December 3, 2020
Contact:ABBVIE CALL CENTER
Email:abbvieclinicaltrials@abbvie.com
Phone:847.283.8955

Use our guide to learn which trials are right for you!

A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating
venetoclax in combination with azacitidine in subjects with treatment-naïve higher-risk MDS
comprising a dose-escalation portion and a safety expansion portion.


Inclusion Criteria:

- Participant must have documented diagnosis of de novo MDS with:

- International Prognostic Scoring System (IPSS) risk categories Int-2 or High
(IPSS overall score ≥ 1.5) and

- Presence of less than 20% bone marrow blasts per bone marrow

- Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to
2.

- Participant is not a candidate to undergo intensive chemotherapy or allogeneic
hematopoietic stem cell transplantation (HSCT).

Exclusion Criteria:

- Participant has received prior therapy for MDS. (Prior supportive care in form of
transfusions or growth factors, etc., is not considered prior therapy.)

- Participant has received prior therapy with a BH3 mimetic.

- Participant has a diagnosis other than previously untreated de novo MDS with IPSS risk
categories Int-2 or High, including:

- MDS with IPSS risk categories Low or Int-1 (overall IPSS score < 1.5)

- Therapy-related MDS (t-MDS)

- MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)

- MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic
myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and
unclassifiable MDS/MPN

- Participant has received allogeneic HSCT or solid organ transplantation.

- Participant has received a live attenuated vaccine within 4 weeks prior to the first
dose of study drug.
We found this trial at
13
sites
Boston, Massachusetts 02111
?
mi
from
Boston, MA
Click here to add this to my saved trials
Baltimore, Maryland 21201
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Avenue
Boston, Massachusetts 02211
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60637
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Concord,
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Nashville, Tennessee 37232
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15260
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
660 South Euclid Avenue
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
1501 North Campbell Avenue
Tucson, Arizona 85724
?
mi
from
Tucson, AZ
Click here to add this to my saved trials